Fenju B. Liu

Suzhou, 215123, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 29 publications

FLASH X-ray spares intestinal crypts from pyroptosis initiated by cGAS-STING activation upon radioimmunotherapy.

FLASH X-ray spares intestinal crypts from pyroptosis initiated by cGAS-STING activation upon radioimmunotherapy.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: October 18, 2022

Corrigendum to "Quantitative assessment of HR and NHEJ activities via CRISPR/Cas9-induced oligodeoxynucleotide-mediated DSB repair" [DNA Repair 70 (2018) 67-71].

Corrigendum to "Quantitative assessment of HR and NHEJ activities via CRISPR/Cas9-induced oligodeoxynucleotide-mediated DSB repair" [DNA Repair 70 (2018) 67-71].

Journal: DNA repair

Published: September 20, 2021

NAD+ depletion radiosensitizes 2-DG-treated glioma cells by abolishing metabolic adaptation.

NAD+ depletion radiosensitizes 2-DG-treated glioma cells by abolishing metabolic adaptation.

Journal: Free radical biology & medicine

Published: September 15, 2020

TIGAR/AP-1 axis accelerates the division of Lgr5- reserve intestinal stem cells to reestablish intestinal architecture after lethal radiation.

TIGAR/AP-1 axis accelerates the division of Lgr5- reserve intestinal stem cells to reestablish intestinal architecture after lethal radiation.

Journal: Cell death & disease

Published: March 17, 2020

Robo1-specific CAR-NK Immunotherapy Enhances Efficacy of 125I Seed Brachytherapy in an Orthotopic Mouse Model of Human Pancreatic Carcinoma.

Robo1-specific CAR-NK Immunotherapy Enhances Efficacy of 125I Seed Brachytherapy in an Orthotopic Mouse Model of Human Pancreatic Carcinoma.

Journal: Anticancer research

Published: August 27, 2019

IDH1-R132H mutation radiosensitizes U87MG glioma cells via epigenetic downregulation of TIGAR.

IDH1-R132H mutation radiosensitizes U87MG glioma cells via epigenetic downregulation of TIGAR.

Journal: Oncology letters

Published: April 11, 2019

Genome-Wide Profiling of the Toxic Effect of Bortezomib on Human Esophageal Carcinoma Epithelial Cells.

Genome-Wide Profiling of the Toxic Effect of Bortezomib on Human Esophageal Carcinoma Epithelial Cells.

Journal: Technology in cancer research & treatment

Published: April 10, 2019

Radiosensitivity enhancement by combined treatment of nimotuzumab and celecoxib on nasopharyngeal carcinoma cells.

Radiosensitivity enhancement by combined treatment of nimotuzumab and celecoxib on nasopharyngeal carcinoma cells.

Journal: Drug design, development and therapy

Published: July 25, 2018

Quantitative assessment of HR and NHEJ activities via CRISPR/Cas9-induced oligodeoxynucleotide-mediated DSB repair.

Quantitative assessment of HR and NHEJ activities via CRISPR/Cas9-induced oligodeoxynucleotide-mediated DSB repair.

Journal: DNA repair

Published: June 26, 2018

A CRISPR/Cas9-Based Screening for Non-Homologous End Joining Inhibitors Reveals Ouabain and Penfluridol as Radiosensitizers.

A CRISPR/Cas9-Based Screening for Non-Homologous End Joining Inhibitors Reveals Ouabain and Penfluridol as Radiosensitizers.

Journal: Molecular cancer therapeutics

Published: January 27, 2017

TIGAR knockdown radiosensitizes TrxR1-overexpressing glioma in vitro and in vivo via inhibiting Trx1 nuclear transport.

TIGAR knockdown radiosensitizes TrxR1-overexpressing glioma in vitro and in vivo via inhibiting Trx1 nuclear transport.

Journal: Scientific reports

Published: October 10, 2016

ZNF185 inhibits growth and invasion of lung adenocarcinoma cells through inhibition of the akt/gsk3β pathway.

ZNF185 inhibits growth and invasion of lung adenocarcinoma cells through inhibition of the akt/gsk3β pathway.

Journal: Journal of biological regulators and homeostatic agents

Published: September 23, 2016

Showing 1-12 of 29

Last Updated: 09/26/2026